The chart below illustrates the status of SAJE’s pipeline programs for the drugs and disease models that have been completed to date. SPL-850 and SPL-891.1, both third generation compounds, have been and are being studied in other animal models of disease. The drug candidates below are being tested in various models of disease using many routes of administration. Safety studies have begun for SPL-850 and SPL-891.1. Because SPL-850 is more active against GSNOR in vitro and in vivo, it is our lead compound and has the most safety data, all of which show safety at high doses.